The International AIDS Vaccine Initiative (IAVI) is a nonprofit scientific organization whose mission is to develop vaccines and other biomedical innovations that prevent HIV infection. Since its founding in 1996, IAVI has provided scientific, research and development and policy leadership to address the needs of communities and key populations at risk for HIV infection around the world. IAVI works with more than 100 academic, industry, government, civil society, clinical and community partners in more than 25 countries. IAVI is committed to supporting the broad field of HIV vaccine research and to fostering collaborations that accelerate the development and availability of new prevention tools. In pursuit of our goals, we work to catalyze and support novel partnership models that engage partners from both the public and private sectors across the product development continuum.
IAVI’s global reach, including its clinical research network in five countries in Sub-Saharan Africa and in India, has allowed IAVI to make fundamental contributions to understanding of the epidemiology, transmission, natural history, virology and immunology of HIV infection. This work played a key role in facilitating the structure-based design of promising HIV vaccine candidates as well as the discovery of “broadly neutralizing antibodies” that are now being advanced as promising approaches for HIV prevention. IAVI’s integrated capabilities in vaccine discovery, development and clinical research take advantage of biopharmaceutical industry expertise to accelerate the development and testing of novel HIV vaccine candidates.
In addition to its core HIV vaccine effort, IAVI is working to amplify its global health impact by working with partners to address other urgent unmet public health needs – such as vaccines for other infectious diseases – where our existing technologies, assets and experience can add unique value.
- Discovers new vaccines and other ways to prevent HIV
- Accelerates vaccine candidates to the clinic through laboratories in the U.S., India, Africa, and the U.K.
- Engages with at-risk populations and strengthens in-country vaccine research capacity through our network of clinical research partners in Africa
- Partners with leading scientists in academia, government, and industry in the U.S. and Europe, applying biopharma product development expertise to develop novel products tailored to the needs of at-risk populations
- Shares resources with other innovators to help the HIV research community as a whole succeed
- Extends core capabilities in vaccine and monoclonal antibody discovery and development to solving other global health challenges
Financial and Operational Highlights
- Approximately 180 employees (~80 located at Headquarters in New York)
- Offices in Amsterdam, New York, Johannesburg, Delhi, and Nairobi along with laboratories in La Jolla, London, Delhi, and Brooklyn.
- Total revenue of $100.6 million